Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
Critical Reviews™ in Eukaryotic Gene Expression
Fator do impacto: 1.841 FI de cinco anos: 1.927 SJR: 0.649 SNIP: 0.516 CiteScore™: 1.96

ISSN Imprimir: 1045-4403
ISSN On-line: 2162-6502

Critical Reviews™ in Eukaryotic Gene Expression

DOI: 10.1615/CritRevEukarGeneExpr.v6.i2-3.10
pages 103-113

The Utilization of Nuclear Matrix Proteins for Cancer Diagnosis

Tracy S. Replogle-Schwab
The University of Michigan Comprehensive Cancer Center and Division of Hematology/Oncology, Department of Internal Medicine, 5510 MSRB 1,1150 W. Medical Center Drive, Ann Arbor, Michigan, 48109-0680
Kenneth J. Pienta
Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, Ml 48109-0680
Robert H. Getzenberg
University of Pittsburgh Cancer Institute, В ST ЕЮ56, 200 Lothrop Street, Pittsburgh, Pennsylvania, 15213-2582


There is a great need for improved biomarkers in the areas of cancer diagnosis and treatment. Cancer-specific nuclear matrix proteins may provide clinicians with improved biomarkers for earlier diagnosis as well as improved therapies. The nuclear matrix is the RNA-protein skeleton of the nucleus that has structural and functional roles within the cell. Nuclear matrix proteins of a variety of cell lines and tissues, both normal and cancerous, have now been examined and are beginning to be characterized. After comparison of tumor and normal cell nuclear matrix protein compositions, it has been determined that there are a set of proteins common to all tissues as well as distinct tissue-specific and cancer-specific differences. It is these protein differences that provide possible novel biomarkers that may allow for earlier detection of cancer and thus potentially increase the chance of survival.